12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Company News  |  Deals

Immunomedics, Takeda deal

Immunomedics disclosed in its fiscal 3Q13 earnings for the period ended March 31 that Takeda's Nycomed company will pursue clinical development of subcutaneous veltuzumab for systemic lupus erythematosis (SLE) as the lead indication instead of rheumatoid...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >